Testing a diabetes drug for nonobstructive hypertrophic cardiomyopathy
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a common diabetes drug (SGLT2 inhibitor) to see if it helps people with nonobstructive hypertrophic cardiomyopathy (HCM). The medicine may improve how your heart works and how well you can exercise.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have nonobstructive HCM with symptoms or limited exercise ability
- You have been on stable heart medications for at least 1 month
- Your heart’s pumping strength (ejection fraction) is above 50%
- You do not have type 1 diabetes or advanced kidney disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a drug can help suppress sugar uptake in the heart for clearer imaging. It may help researchers understand how to better see heart problems.
This trial studies whether two medicines—an SGLT2 inhibitor and potassium nitrate—can improve symptoms and heart function in people with heart failure with preserved ejection fraction (HFpEF). It focuses on people who still have signs of “stiff” or high filling pressure in the heart despite a normal-ish ejection fraction.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
This trial tests whether the drug henagliflozin can reduce scarring in the heart muscle of people with a type of hypertrophic cardiomyopathy that does not block blood flow. It uses special scans to measure scar tissue before and after treatment.
This trial tests whether an SGLT2 inhibitor (a type of diabetes drug) can help prevent heart attacks, strokes, and other heart problems in people with high blood pressure. You may be eligible if you are 60 or older, have high blood pressure, and have had a heart or blood vessel event (like a heart attack or stroke) or have certain risk factors (like smoking, high cholesterol, or obesity).
This study tests whether a type of diabetes medication called an SGLT2 inhibitor can improve the structure and function of the heart's left atrium in people with type 2 diabetes. It may help prevent heart problems in the future.
Hear when a new Hypertrophic Cardiomyopathy Without Obstruction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.